TY - JOUR
T1 - Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms
AU - Lowe, Franklin C.
N1 - Funding Information:
This article was supported by a grant from Sanofi-Synthelabo, Inc., New York, New York. Dr. /owe is a speaker, researcher, and member of the advisory boards of Merck 6~ Co., Inc., Whitehouse Station, New Jersey; Boehringer-Ingelheml Pharmaceuticals, Inc., Ridgefield, Connecticut; and Sanofi-Synthelabo, Inc.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2004/11
Y1 - 2004/11
N2 - Although initially introduced for the management of hypertension, alpha 1-adrenergic-receptorantagonists (a1-blockers) have become the standard of care for the medical management of benign prostatic hyperplasia (BPH)-related lower urinary tract symptoms (LUTS). However, these agents have the potential to produce orthostatic hypotension and other blood pressure-related adverse effects in normotensive patients and in those receiving concurrent treatment with other antihypertensive agents. As a result, more "uroselective," less vasoactive α1-blockers have been developed. This article reviews current information on the role of α1-blockers in the treatment of BPH-related LUTS. The focus is on tamsulosin and alfuzosin, newer "uroselective" agents in this class that have a decreased potential for cardiovascular adverse effects. Relevant articles were identified through a search of the English-language literature indexed onMEDLINE and the proceedings of scientific meetings from 1976 to 2003. The search terms were benign prostatic hyperplasia treatment, alpha1-adrenergic-receptor blockep uroselectivity, lower urinary tract symptoms, complications, and cardiovascular. Tamsulosin has selectivity for the a α1 and α1d receptor subtypes. Alfuzosin, although not receptorsubtypeselective, is clinically "uroselective" and does not significantly affect vascular alpha-adrenergic receptors. Both agents are efficacious in relieving LUTS and have a decreased potential for such cardiovascular adverse effects as postural hypotension. Common adverse events with these agents include dizziness and asthenia. Based on the available data, "uroselective" α1-blockers should be considered over older, morevasoactive agents for the medical management of LUTS, particularly in patients with BPH and hypertension.
AB - Although initially introduced for the management of hypertension, alpha 1-adrenergic-receptorantagonists (a1-blockers) have become the standard of care for the medical management of benign prostatic hyperplasia (BPH)-related lower urinary tract symptoms (LUTS). However, these agents have the potential to produce orthostatic hypotension and other blood pressure-related adverse effects in normotensive patients and in those receiving concurrent treatment with other antihypertensive agents. As a result, more "uroselective," less vasoactive α1-blockers have been developed. This article reviews current information on the role of α1-blockers in the treatment of BPH-related LUTS. The focus is on tamsulosin and alfuzosin, newer "uroselective" agents in this class that have a decreased potential for cardiovascular adverse effects. Relevant articles were identified through a search of the English-language literature indexed onMEDLINE and the proceedings of scientific meetings from 1976 to 2003. The search terms were benign prostatic hyperplasia treatment, alpha1-adrenergic-receptor blockep uroselectivity, lower urinary tract symptoms, complications, and cardiovascular. Tamsulosin has selectivity for the a α1 and α1d receptor subtypes. Alfuzosin, although not receptorsubtypeselective, is clinically "uroselective" and does not significantly affect vascular alpha-adrenergic receptors. Both agents are efficacious in relieving LUTS and have a decreased potential for such cardiovascular adverse effects as postural hypotension. Common adverse events with these agents include dizziness and asthenia. Based on the available data, "uroselective" α1-blockers should be considered over older, morevasoactive agents for the medical management of LUTS, particularly in patients with BPH and hypertension.
KW - adrenergic-receptor antagonist
KW - complications
KW - hypertension
KW - prostatic hyperplasia
UR - http://www.scopus.com/inward/record.url?scp=11844264906&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=11844264906&partnerID=8YFLogxK
U2 - 10.1016/j.clinthera.2004.11.006
DO - 10.1016/j.clinthera.2004.11.006
M3 - Article
C2 - 15639685
AN - SCOPUS:11844264906
SN - 0149-2918
VL - 26
SP - 1701
EP - 1713
JO - Clinical Therapeutics
JF - Clinical Therapeutics
IS - 11
ER -